[go: up one dir, main page]

ECSP13013106A - Composición farmacéutica oftalmológica tópica que contiene regorafenib. - Google Patents

Composición farmacéutica oftalmológica tópica que contiene regorafenib.

Info

Publication number
ECSP13013106A
ECSP13013106A EC2013013106A ECSP13013106A ECSP13013106A EC SP13013106 A ECSP13013106 A EC SP13013106A EC 2013013106 A EC2013013106 A EC 2013013106A EC SP13013106 A ECSP13013106 A EC SP13013106A EC SP13013106 A ECSP13013106 A EC SP13013106A
Authority
EC
Ecuador
Prior art keywords
typical
pharmaceutical composition
composition containing
containing regorafenib
ophthalmological pharmaceutical
Prior art date
Application number
EC2013013106A
Other languages
English (en)
Inventor
Andreas Ohm
Jörg Keldenich
Bernd Riedl
Degenfeld Georges Von
Michael Böttger
Julia Freundlieb
Dietrich Claudia Hirth
Jürgen Klar
Uwe Muenster
Annett Richter
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46456546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13013106(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of ECSP13013106A publication Critical patent/ECSP13013106A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas oftalmológicas tópicas que contienen regorafenib, un hidrato, solvato o sal farmacéuticamente aceptable del mismo o un polimorfo del mismo y su procedimiento de preparación y su uso para el tratamiento de trastornos oftalmológicos.
EC2013013106A 2011-06-28 2013-12-24 Composición farmacéutica oftalmológica tópica que contiene regorafenib. ECSP13013106A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11171719 2011-06-28
EP12155281 2012-02-14

Publications (1)

Publication Number Publication Date
ECSP13013106A true ECSP13013106A (es) 2014-01-31

Family

ID=46456546

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2013013106A ECSP13013106A (es) 2011-06-28 2013-12-24 Composición farmacéutica oftalmológica tópica que contiene regorafenib.

Country Status (26)

Country Link
US (1) US20140296301A1 (es)
EP (1) EP2726059A1 (es)
JP (1) JP5998213B2 (es)
KR (1) KR20140048218A (es)
CN (1) CN103889399A (es)
AP (1) AP2013007335A0 (es)
AR (1) AR086800A1 (es)
AU (1) AU2012277905A1 (es)
BR (1) BR112013033831A2 (es)
CA (1) CA2840329A1 (es)
CL (1) CL2013003700A1 (es)
CO (1) CO6920289A2 (es)
CR (1) CR20130693A (es)
CU (1) CU24163B1 (es)
DO (1) DOP2013000314A (es)
EA (1) EA201400064A1 (es)
EC (1) ECSP13013106A (es)
GT (1) GT201300322A (es)
HK (1) HK1197176A1 (es)
MX (1) MX2013015287A (es)
PE (1) PE20141031A1 (es)
PH (1) PH12013502691A1 (es)
TN (1) TN2013000533A1 (es)
UY (1) UY34166A (es)
WO (1) WO2013000917A1 (es)
ZA (1) ZA201400646B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA91520C2 (en) 2004-09-29 2010-08-10 Баер Шеринг Фарма Акциенгезельшафт Thermodynamically stable form of tosylate
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
UY35183A (es) * 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2015011659A1 (en) * 2013-07-24 2015-01-29 Dr. Reddys Laboratories Limited Crystalline polymorphic forms of regorafenib and processes for the preparation of polymorph i of regorafenib
CN103923000A (zh) * 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 几种新晶型及其制备方法
CN104546776B (zh) * 2015-02-10 2017-08-22 杭州朱养心药业有限公司 瑞戈非尼片剂药物组合物和制法
CN114010787A (zh) * 2015-06-06 2022-02-08 拨云生物医药科技(广州)有限公司 用于治疗翼状胬肉的组合物和方法
WO2017210130A1 (en) 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for improving glaucoma surgery success

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732222B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
TR201815573T4 (tr) * 2002-05-28 2018-11-21 Astrazeneca Ab Topikal olarak uygulanabilir farmasötik preparasyon.
PT1663978E (pt) * 2003-07-23 2008-02-15 Bayer Pharmaceuticals Corp Omega-carboxiaril difenil ureia substituída por flúor para o tratamento e a prevenção de doenças e estados patológicos
SI1885336T1 (sl) 2005-05-10 2009-08-31 Alcon Inc Suspenzijske formulacije, ki obsegajo aktivno sestavino, poloksamerni ali meroksapolni surfaktant in glikol, in njihova uporaba za pripravo zdravila za zdravljenje oftalmičnih motenj
CA2611720A1 (en) 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
BRPI0619057A2 (pt) 2005-11-29 2011-09-20 Smithkline Beecham Corp formulação farmacêutica de uso tópico, uso de um ou mais compostos, e, compostos
WO2007068382A1 (en) * 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl urea for treating inflammatory skin. eye and/or ear diseases
JP2009521493A (ja) 2005-12-23 2009-06-04 アルコン，インコーポレイテッド 眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤
WO2008027341A2 (en) 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
RU2470635C2 (ru) * 2007-05-11 2012-12-27 Сантен Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза
DE102007055341A1 (de) * 2007-11-19 2009-05-20 Bayer Animal Health Gmbh Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
EP3028707A1 (en) 2009-05-01 2016-06-08 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
MX2012000706A (es) 2009-07-16 2012-06-01 Glaxo Wellcome Mfg Pte Ltd Metodo de tratamiento.

Also Published As

Publication number Publication date
NZ619229A (en) 2016-04-29
JP2014518233A (ja) 2014-07-28
US20140296301A1 (en) 2014-10-02
CA2840329A1 (en) 2013-01-03
DOP2013000314A (es) 2014-04-15
WO2013000917A1 (en) 2013-01-03
BR112013033831A2 (pt) 2017-02-14
CU20130168A7 (es) 2014-04-24
EA201400064A1 (ru) 2014-05-30
AP2013007335A0 (en) 2013-12-31
CN103889399A (zh) 2014-06-25
CU24163B1 (es) 2016-03-31
AU2012277905A8 (en) 2014-01-30
CO6920289A2 (es) 2014-04-10
GT201300322A (es) 2014-11-13
UY34166A (es) 2013-01-31
AU2012277905A1 (en) 2014-01-16
EP2726059A1 (en) 2014-05-07
KR20140048218A (ko) 2014-04-23
PH12013502691A1 (en) 2017-08-23
AR086800A1 (es) 2014-01-22
HK1197176A1 (en) 2015-01-09
MX2013015287A (es) 2014-03-31
PE20141031A1 (es) 2014-08-21
CL2013003700A1 (es) 2014-07-18
JP5998213B2 (ja) 2016-09-28
TN2013000533A1 (en) 2015-03-30
CR20130693A (es) 2016-05-02
ZA201400646B (en) 2015-11-25

Similar Documents

Publication Publication Date Title
PE20151005A1 (es) Composicion farmaceutica recubierta que contiene regorafenib
DOP2013000314A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2013188273A8 (en) Topical ophthalmological pharmaceutical composition containing axitinib
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
WO2013188268A8 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
WO2013188283A8 (en) Topical ophthalmological pharmaceutical composition containing sunitinib
MX2014003169A (es) Ligandos del receptor ep1.
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
CR20150327A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2013188279A8 (en) Topical ophthalmological pharmaceutical composition containing cediranib
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора
DOP2015000049A (es) Composición farmacéutica recubierta que contiene regorafenib